Christopher Rudolf, Founder and CEO of Volv Global SA, took part in the panel with Martine Zimmermann, Global Head of Regulatory Affairs, Alexion Pharmaceuticals, Inc, Javier Jimenez, EVP RWE & Late Phase, Syneos Health and Matt Eagles, Head of Patient Engagement, Havas Lynx Group to discuss RWE and patient-centricity for World Rare Disease Day.
Artificial Intelligence (AI)-driven biomarker discovery innovators Scailyte and Volv Global, today announced a strategic partnership to develop a patient identification and diagnostic platform for rare diseases.
Determining patient prevalence with rare and ultra-rare diseases has long been a challenge for industry, investors and payers. Accurate prevalence data, along with the ability to locate patients that could benefit from a breakthrough ATMP, will enable companies to present their value story from the start of the R&D journey. Come and see us talk about this and more at the event.
Volv were excited to be at the World Orphan Drug Congress virtual event as Platinum sponsor. People have requested that the video of our talk be reposted on-line, as they missed it at the event, so it has been reposted here for you.
Healthcare: The Big Shark Tank Our healthcare ecosystem has also gone the same way. Today, healthcare is no longer a house call by a local doctor who knows our history by simple familiarity and through their own paper records. . .
February 29th, 2020, is not only a rare leap year day, but also Rare Disease Day, an observance organized by the European Organization of Rare Diseases (EURORDIS) and supported by the National Organization of Rare Diseases (NORD) to raise awareness for unknown or overlooked illnesses.[...]